The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations
Open accessAbstract
This evidence‐ and consensus‐based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 6,935
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Definition of treatment goals for moderate to severe psoriasis: a European consensus
Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., Franke, J., Antoniou, C., Arenberger, P., Balieva, F., et al. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-010-1080-1 · Cited by 898
Self-citationPhase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Pathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., et al. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03389.x · Cited by 703
Self-citationPapp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C., Stevens, R. M., Day, R. M., Gordon, K. B., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.03.049 · Cited by 678
Self-citationBurmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J., & Lacerda, A. P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201244 · Cited by 591
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Paul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Self-citationSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Self-citationVan Ede, A. E., Laan, R. F. J. M., Rood, M. J., Huizinga, T. W. J., Van De Laar, M. A. F. J., Denderen, C. J. V., Westgeest, T. A. A., Romme, T. C., De Rooij, D.-J. R. A. M., Jacobs, M. J. M., et al. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1515::aid-art273>3.0.co;2-7 · Cited by 401
Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Arenberger, P., Bachelez, H., Barker, J., Dauden, E., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13354 · Cited by 399
Self-citationShea, B., Swinden, M. V., Tanjong Ghogomu, E., Ortiz, Z., Katchamart, W., Rader, T., Bombardier, C., Wells, G. A., & Tugwell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000951.pub2 · Cited by 347
Dubertret, L., Mrowietz, U., Ranki, A., Van De Kerkhof, P. C. M., Chimenti, S., Lotti, T., Schäfer, G., & survey, E. P. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07405.x · Cited by 329
Self-citationLong-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.719 · Cited by 324
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1882-2 · Cited by 292
Self-citationPapp, K., Cather, J. C., Rosoph, L., Sofen, H., Langley, R. G., Matheson, R. T., Hu, C., & Day, R. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60642-4 · Cited by 282
den Broeder, A. A., Creemers, M. C. W., Fransen, J., et al. (2007) · PubMed · Cited by 280
Augustin, M., Krüger, K., Radtke, M. A., Schwippl, I., & Reich, K. (2008) · Dermatology · doi:10.1159/000119415 · Cited by 271
Self-citationSaunte, D. M., Mrowietz, U., Puig, L., & Zachariae, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15015 · Cited by 270
Self-citationFrench guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults
Amatore, F., Villani, A. ‐., Tauber, M., Viguier, M., Guillot, B., & the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie) (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15340 · Cited by 232
Werner, R. N., Nikkels, A. F., Marinović, B., Schäfer, M., Czarnecka‐Operacz, M., Agius, A. M., Bata‐Csörgő, Z., Breuer, J., Girolomoni, G., Gross, G. E., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13957 · Cited by 222
Self-citationItalian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis
Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, A., Costanzo, A., Conti, A., Dapavo, P., De Simone, C., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14114 · Cited by 182
Self-citationPsychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Le Cleach, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub4 · Cited by 170
Self-citationMahil, S. K., Wilson, N., Dand, N., Reynolds, N. J., Griffiths, C. E. M., Emsley, R., Marsden, A., Evans, I., Warren, R. B., Stocken, D., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18333 · Cited by 164
Self-citationGottlieb, A. B., Blauvelt, A., Thaçi, D., Leonardi, C. L., Poulin, Y. P., Drew, J., Peterson, L., Arendt, C. H., Burge, D. J., & Reich, K. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.012 · Cited by 157
Self-citationReich, K., Warren, R. B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S. J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18232 · Cited by 149
Self-citationNast, A., Spuls, P. I., van der Kraaij, G. E., Gisondi, P., Paul, C. F., Ormerod, A. D., Saïag, P., Smith, C. H., Daudén, E., de Jong, E. M. G. J., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14454 · Cited by 136
Self-citationDaudén, E., Puig, L., Ferrándiz, C., Sánchez‐Carazo, J. L., & Hermosa, J. M. H. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13542 · Cited by 134
Lebwohl, M., Blauvelt, A., Paul, C. F., Sofen, H. L., Węgłowska, J., Piguet, V., Burge, D. J., Rolleri, R., Drew, J., Peterson, L., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.013 · Cited by 134
Ortiz, Z., Shea, B., Suarez-Almazor, M. E., Moher, D., Wells, G. A., & Tugwell, P. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000951 · Cited by 126
Lortholary, O., Πετρίκκος, Γ., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12042 · Cited by 117
Werner, R. N., Nikkels, A., Marinović, B., Schäfer, M., Czarnecka-Operacz, M. M., Agius, A. M., Bata‐Csörgõ, Z., Breuer, J., Girolomoni, G., Gross, G., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13995 · Cited by 106
Self-citationThe Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects
Mrowietz, U., Morrison, P. J., Suhrkamp, I., Kumanova, M., & Clement, B. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.002 · Cited by 104
Self-citationPapp, K. A., Poulin, Y. P., Bissonnette, R., Bourcier, M., Toth, D. P., Rosoph, L., Poulin-Costello, M., Setterfield, M., & Syrotuik, J. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.07.026 · Cited by 100
Puig, L., Lebwohl, M., Bachelez, H., Sobell, J. M., & Jacobson, A. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.095 · Cited by 83
Esposito, M., Giunta, A., Mazzotta, A., et al. (2012) · Dermatology · doi:10.1159/000345623 · Cited by 79
Guidelines for the Use of Acitretin in Psoriasis
Carretero, G., Ribera, M., Belinchón, I., Carrascosa, J. M., Puig, L., Ferrándiz, C., Dehesa, L. A., Vidal, D., Peral, F., Jorquera, E., et al. (2013) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2013.01.001 · Cited by 75
Egeberg, A., Andersen, Y. M. F., Halling, A., Alignahi, F., Thyssen, J. P., Burge, R. T., & Mallbris, L. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15920 · Cited by 70
Acitretina: guía de uso en psoriasis
Carretero, G., Ribera, M., Belinchón, I., Carrascosa, J. M., Puig, L., Ferrándiz, C., Dehesa, L. A., Vidal, D., Peral, F., Jorquera, E., et al. (2013) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2013.01.003 · Cited by 55
Treatment goals for psoriasis: Should PASI 90 become the standard of care?
Torres, T. R., & Puig, L. (2014) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2014.10.001 · Cited by 54
Lebwohl, M., Blauvelt, A., Menter, A., Papp, K. A., Guenthner, S., Pillai, R., Israel, R. J., & Jacobson, A. A. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00466-2 · Cited by 44
Treatment goals for psoriasis: Should PASI 90 become the standard of care?
Torres, T. R., & Puig, L. (2015) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2014.10.005 · Cited by 40
Wang, X., Liu, Q., Wu, L., Nie, Z., & Mei, Z. (2019) · Journal of Cancer · doi:10.7150/jca.37015 · Cited by 39
Combined Use of Systemic Agents for Psoriasis
Busard, C. I., Zweegers, J., Limpens, J., Langendam, M. W., & Spuls, P. I. (2014) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.1111 · Cited by 36
Self-citationDo antitumor necrosis factor agents increase the risk of postoperative orthopedic infections?
Pappas, D. A., & Giles, J. T. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282fcc345 · Cited by 34
Melo, F. J., & Magina, S. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14072 · Cited by 32
Khatri, A., Cheng, L., Camez, A. A., Ignatenko, S., Pang, Y., & Othman, M. I. A. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0730-x · Cited by 29
Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017
van der Kraaij, G. E., Balak, D., Busard, C. I., van Cranenburgh, O. D., Chung, Y., Driessen, R. J. B., de Groot, M., de Jong, E. M. G. J., Kemperman, P. M. J. H., de Kort, W. J. A., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17198 · Cited by 26
Self-citationNast, A., Dilleen, M., Liyanage, W., Aikman, L., Szczypa, P., & Dressler, C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15864 · Cited by 9
Self-citationWhat Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.
Hashim, P. W., Chen, T., Lebwohl, M., Marangell, L. B., & Kircik, L. (2018) · PubMed · Cited by 9
Pham, P. A., Dressler, C., Eisert, L., Nast, A., & Werner, R. N. (2019) · Rheumatology International · doi:10.1007/s00296-019-04244-5 · Cited by 8
Self-citation
Cited by
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Cascio Ingurgio, R., Alfano, A., Matteodo, E., Ibba, L., Gargiulo, L., Paolino, G., Mercuri, S. R., Carugno, A., Zerbinati, N., Bighetti, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020631 · Cited by 3
Metadata
- Authors
- Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata‐Csörgö, Z., Boonen, H., De Jong, E., Garcia‐Doval, I., Gisondi, P., Kaur‐Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., Schmitt‐Egenolf, M., Sikora, M., Strömer, K., Sundnes, O., Trigos, D., Van Der Kraaij, G., Yawalkar, N., & Dressler, C.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2020-11
- Volume
- 34
- Issue
- 11
- Pages
- 2461-2498
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W3116148367
- Cited by
- 420
- References
- 62
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.